Answers are grounded in this paper and cite their sources.
Evaluation of androgen receptor and immune characteristics in metastatic triple-negative breast cancer, suggesting better survival potential for certain biomarkers.
HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers.
No takes yet. Share an insight, caveat, or question.
Tarantino et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: